Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab Emtansine and Pyrotinib in HER2+ Metastatic Breast Cancer
NCT05560308Phase 2Unknown
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Sep 2022
- Primary completion
- Aug 2024
- Modality
- Fragment-Derived Small Molecules, Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
01
Overview
A Phase 2 trial of trastuzumab emtansine, pyrotinib in breast cancer, sponsored by Tianjin Medical University Cancer Institute and Hospital. Status: unknown.
02
Drugs
trastuzumab emtansinepyrotinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05560308.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05560308.